220 related articles for article (PubMed ID: 12037505)
41. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
Pratley RE; Urosevic D; Boldrin M; Balena R;
Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
[TBL] [Abstract][Full Text] [Related]
42. [Rosiglitazone (BRL-49653)].
Oka Y
Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
[No Abstract] [Full Text] [Related]
43. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
44. New therapeutic options: management strategies to optimize glycemic control.
Sisam DA
J Am Osteopath Assoc; 2011 Apr; 111(4):300; author reply 300. PubMed ID: 21562302
[No Abstract] [Full Text] [Related]
45. [Value of glitazones in therapy of type 2 diabetes: pro].
Pfohl M
Dtsch Med Wochenschr; 2001 May; 126(20):605. PubMed ID: 11402928
[No Abstract] [Full Text] [Related]
46. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
47. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
48. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness and side effects of thiazolidinediones for type 2 diabetes.
Morton AP; McIntyre HD
Med J Aust; 2005 May; 182(9):492-3. PubMed ID: 15865597
[No Abstract] [Full Text] [Related]
51. [Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
Fehér J; Lengyel G
Orv Hetil; 2007 Dec; 148(49):2331-5. PubMed ID: 18048112
[TBL] [Abstract][Full Text] [Related]
52. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes.
Vongthavaravat V; Wajchenberg BL; Waitman JN; Quimpo JA; Menon PS; Ben Khalifa F; Chow WH;
Curr Med Res Opin; 2002; 18(8):456-61. PubMed ID: 12564655
[TBL] [Abstract][Full Text] [Related]
53. Thiazolidinediones and clinical outcomes in type 2 diabetes.
Retnakaran R; Zinman B
Lancet; 2009 Jun; 373(9681):2088-90. PubMed ID: 19501899
[No Abstract] [Full Text] [Related]
54. [Glitazones and weight gain].
Scheen A
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S41-4. PubMed ID: 12037507
[No Abstract] [Full Text] [Related]
55. Pharmacoeconomic evaluation of glimepiride combined with other drugs in the treatment of diabetes.
Liu X; Zeng L; Xu W
Pak J Pharm Sci; 2018 May; 31(3(Special)):1103-1107. PubMed ID: 29735458
[TBL] [Abstract][Full Text] [Related]
56. Combination oral agent and insulin therapy for type 2 diabetes mellitus.
Passaro MD; Ratner RE
Curr Diab Rep; 2001 Oct; 1(2):106-11. PubMed ID: 12643105
[TBL] [Abstract][Full Text] [Related]
57. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population.
Roy R; Navar M; Palomeno G; Davidson MB
Diabetes Care; 2004 Jul; 27(7):1741-2. PubMed ID: 15220256
[No Abstract] [Full Text] [Related]
58. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
[TBL] [Abstract][Full Text] [Related]
59. Authors' reply.
Kalra S; Singh V
J Postgrad Med; 2014; 60(3):344. PubMed ID: 25272399
[No Abstract] [Full Text] [Related]
60. Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Pokharna H; Kanna B
Diabetes Obes Metab; 2007 Nov; 9(6):914. PubMed ID: 17394564
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
